RadioMedix

Executive Summary

RadioMedix is a clinical-stage biotechnology company headquartered in St. Louis, Missouri, specializing in targeted radiopharmaceuticals for the diagnosis and treatment of cancer, with a primary focus on neuroendocrine tumors (NETs) and other rare cancers. Founded in 2006, the company has advanced its proprietary platform that combines tumor-targeting peptides with therapeutic or diagnostic radioactive isotopes. Its first commercial product, Detectnet (copper Cu 64 dotatate), is a PET imaging agent approved by the FDA for the localization of somatostatin receptor-positive neuroendocrine tumors. In addition to its diagnostic portfolio, RadioMedix is developing a pipeline of radiopharmaceutical therapies, including ²¹²Pb-DOTAMTATE (AlphaMedix), a targeted alpha-particle therapy for NETs currently in Phase 2/3 clinical trials. The company has raised approximately $40 million in funding and employs between 50 and 200 people. With a strong foothold in theragnostics—combining diagnosis and therapy—RadioMedix aims to address significant unmet medical needs in oncology, leveraging the precision of radiopharmaceuticals to deliver radioactive payloads directly to cancer cells while minimizing damage to healthy tissue.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 data readout for 212Pb-DOTAMTATE (AlphaMedix) in neuroendocrine tumors70% success
• Q4 2025FDA approval decision for Detectnet label expansion into new indications60% success
• Q3 2026Potential strategic partnership or licensing deal for the company's pipeline50% success